Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B.

Novartis NOVN0.47%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline.

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

the expected benefits of Novartis’ acquisition of Anthos, the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Anthos Therapeutics, founded in 2019 by Swiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy privately held, clinical-stage US biotech Anthos Therapeutics for up to $3.1 ...

Novartis will acquire Anthos Therapeutics for $925M upfront. The deal is expected to close in H1 2025. Anthos’ abelacimab showed reduced bleeding risks in Phase 2 trials and is in three Phase 3 ...

Feb 11 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's (BX.N), opens new tab drug ...

Novartis has gone full circle with Anthos Therapeutics. The Swiss pharma giant is doubling down on its expertise in the cardiovascular area by acquiring the clinical-stage biotech firm mostly owned by ...

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline. The Swiss ...

Novartis NOVN0.11%increase; green up pointing triangle said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to ...